Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.
Brentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.
Institute of Hematology and Medical Oncology, 'L. & A. Seràgnoli', University of Bologna, Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it.
P L
PL
Zinzani
University Hospital of Cologne, Cologne, Germany.
S
S
Sasse
The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
J
J
Radford
Global Medical Affairs, Millennium Pharmaceuticals Inc., Cambridge, MA, USA(1).
A
A
Gautam
Global Oncology Pricing Market Access and Health Economics, Millennium Pharmaceuticals Inc., Cambridge, MA, USA(1).
V
V
Bonthapally
D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
Antibody-drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma; Named patient program